Total Payments
$22,104
2024 Payments
$1,531
Companies
78
Transactions
1,070
Medicare Patients
17,673
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$21,585 (97.7%)
Other$405.00 (1.8%)
Gifts$59.40 (0.3%)
Education$53.94 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,585 | 1,061 | 97.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $405.00 | 3 | 1.8% |
| Gift | $59.40 | 1 | 0.3% |
| Education | $53.94 | 5 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $2,068 | 115 | $0 (2024) |
| ABBVIE INC. | $1,596 | 121 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,567 | 39 | $0 (2022) |
| GlaxoSmithKline, LLC. | $1,412 | 66 | $0 (2024) |
| Amgen Inc. | $1,183 | 46 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,099 | 36 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,029 | 38 | $0 (2024) |
| PFIZER INC. | $912.12 | 52 | $0 (2024) |
| Allergan, Inc. | $890.56 | 87 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $639.87 | 20 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,531 | 75 | ABBVIE INC. ($250.33) |
| 2023 | $1,583 | 75 | Bayer Healthcare Pharmaceuticals Inc. ($287.97) |
| 2022 | $2,660 | 122 | ABBVIE INC. ($433.12) |
| 2021 | $4,416 | 199 | Janssen Pharmaceuticals, Inc ($743.82) |
| 2020 | $2,663 | 150 | Amgen Inc. ($296.21) |
| 2019 | $3,036 | 140 | SANOFI-AVENTIS U.S. LLC ($585.36) |
| 2018 | $3,578 | 153 | Novo Nordisk Inc ($661.77) |
| 2017 | $2,636 | 156 | Janssen Pharmaceuticals, Inc ($307.70) |
All Payment Transactions
1,070 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.51 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/19/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.16 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Endocrinology | ||||||
| 10/25/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: Endocrinology | ||||||
| 10/23/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Inflammation | ||||||
| 10/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $4.32 | General |
| Category: Obesity | ||||||
| 10/10/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.53 | General |
| Category: NEUROSCIENCE | ||||||
| 10/07/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/04/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: Neurology | ||||||
| 10/03/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $41.04 | General |
| Category: Endocrinology | ||||||
| 09/27/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Diabetes Care | ||||||
| 09/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: PSYCHIATRY | ||||||
| 09/16/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Obesity | ||||||
| 09/11/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.56 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.71 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: PSYCHIATRY | ||||||
| 08/23/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 08/22/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $55.64 | General |
| Category: NEUROLOGY | ||||||
| 08/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Cardio-renal | ||||||
| 08/19/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: OUD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 3,271 | 9,107 | $2.1M | $581,230 |
| 2022 | 40 | 4,174 | 8,473 | $1.6M | $418,856 |
| 2021 | 55 | 5,764 | 10,941 | $1.8M | $544,215 |
| 2020 | 45 | 4,464 | 15,580 | $1.5M | $484,593 |
Total Patients
17,673
Total Services
44,101
Medicare Billing
$2.0M
Procedure Codes
174
All Medicare Procedures & Services
174 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 276 | 3,096 | $1.1M | $279,482 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 284 | 960 | $289,248 | $78,192 | 27.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 142 | 1,112 | $127,865 | $47,588 | 37.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 326 | 326 | $102,074 | $38,423 | 37.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 429 | 491 | $56,420 | $34,483 | 61.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 61 | 91 | $31,165 | $17,983 | 57.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 163 | 297 | $68,183 | $17,361 | 25.5% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 131 | 292 | $69,175 | $14,113 | 20.4% |
| 99344 | Residence visit for new patient with moderate level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 114 | 114 | $57,538 | $10,646 | 18.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 79 | 154 | $14,168 | $5,136 | 36.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 102 | 256 | $44,138 | $4,478 | 10.1% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 28 | 28 | $12,549 | $4,209 | 33.5% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 147 | 147 | $10,641 | $3,599 | 33.8% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 196 | 196 | $9,911 | $3,303 | 33.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 177 | 177 | $8,950 | $2,982 | 33.3% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 58 | 82 | $9,430 | $2,839 | 30.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 81 | 302 | $21,185 | $2,834 | 13.4% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 15 | 16 | $5,520 | $2,390 | 43.3% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 14 | 14 | $6,311 | $2,170 | 34.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 16 | $6,477 | $1,778 | 27.5% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 55 | 74 | $5,361 | $1,767 | 33.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $5,340 | $1,421 | 26.6% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 2023 | 31 | 32 | $3,680 | $857.92 | 23.3% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 47 | 60 | $2,346 | $806.78 | 34.4% |
| 99347 | Residence visit for established patient with straightforward medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 17 | 20 | $3,151 | $651.85 | 20.7% |
About Dr. Ramzi Ghosn, M.D
Dr. Ramzi Ghosn, M.D is a Family Medicine healthcare provider based in Dawsonville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407943301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ramzi Ghosn, M.D has received a total of $22,104 in payments from pharmaceutical and medical device companies, with $1,531 received in 2024. These payments were reported across 1,070 transactions from 78 companies. The most common payment nature is "Food and Beverage" ($21,585).
As a Medicare-enrolled provider, Ghosn has provided services to 17,673 Medicare beneficiaries, totaling 44,101 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 174 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Dawsonville, GA
- Active Since 10/10/2006
- Last Updated 10/12/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1407943301
Products in Payments
- Ozempic (Drug) $851.76
- INVEGA SUSTENNA (Drug) $833.29
- VRAYLAR (Drug) $800.84
- Otezla (Drug) $668.44
- TRELEGY ELLIPTA (Drug) $666.62
- REXULTI (Drug) $651.82
- UBRELVY (Drug) $609.70
- Kerendia (Drug) $545.47
- Vascepa (Drug) $516.00
- KRYSTEXXA (Biological) $495.04
- FARXIGA (Drug) $487.11
- NURTEC ODT (Drug) $459.22
- TROKENDI XR (Drug) $400.29
- XARELTO (Drug) $383.38
- SOLIQUA 100/33 (Drug) $379.48
- SHINGRIX (Biological) $365.15
- NEXLIZET (Drug) $362.09
- Aimovig (Biological) $335.42
- CHANTIX (Drug) $323.35
- MAVYRET (Drug) $309.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Dawsonville
Ernst Nieuwoudt, M.d, M.D
Family Medicine — Payments: $12,268
Family Medicine $12,268
Priya Shah, M.d, M.D
Family Medicine — Payments: $6,290
Family Medicine $6,290
Nabil Keith, Md, MD
Family Medicine — Payments: $6,146
Family Medicine $6,146
Daniel Musser, Md, MD
Family Medicine — Payments: $3,425
Family Medicine $3,425
Dr. Katia Adams, M.d, M.D
Family Medicine — Payments: $3,068
Family Medicine $3,068
Dr. Larry Anderson, D.o, D.O
Family Medicine — Payments: $2,229
Family Medicine $2,229